Search

Your search keyword '"Nassif, Michael E."' showing total 6 results
Start Over Author "Nassif, Michael E." Journal journal of the american college of cardiology
6 results on '"Nassif, Michael E."'

1. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Author

Maron, Martin S., Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Abraham, Theodore P., Arad, Michael, Cardim, Nuno, Choudhury, Lubna, Claggett, Brian, Coats, Caroline J., Düngen, Hans-Dirk, Garcia-Pavia, Pablo, Hagège, Albert A., Januzzi, James L., Kulac, Ian, Lee, Matthew M.Y., Lewis, Gregory D., Ma, Chang-Sheng, Michels, Michelle, Oreziak, Artur, Owens, Anjali T., Spertus, John A., Solomon, Scott D., Tfelt-Hansen, Jacob, van Sinttruije, Marion, Veselka, Josef, Watkins, Hugh C., Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, and Olivotto, Iacopo

Published
2024
Full Text
View/download PDF

2. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Author

Masri, Ahmad, Choudhury, Lubna, Barriales-Villa, Roberto, Elliott, Perry, Maron, Martin S., Nassif, Michael E., Oreziak, Artur, Owens, Anjali Tiku, Saberi, Sara, Tower-Rader, Albree, Rader, Florian, Garcia-Pavia, Pablo, Olivotto, Iacopo, Nagueh, Sherif F., Wang, Andrew, Heitner, Stephen B., Jacoby, Daniel L., Kupfer, Stuart, Malik, Fady I., Melloni, Chiara, Meng, Lisa, Wei, Jenny, Sherrid, Mark V., and Abraham, Theodore P.

Published
2024
Full Text
View/download PDF

3. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Author

Sherrod, Charles F., IV, Saberi, Sara, Nassif, Michael E., Claggett, Brian L., Coats, Caroline J., Garcia-Pavia, Pablo, Januzzi, James L., Lewis, Gregory D., Ma, Changsheng, Maron, Martin S., Miao, Zi Michael, Olivotto, Iacopo, Veselka, Josef, Butzner, Michael, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, and Spertus, John A.

Published
2024
Full Text
View/download PDF

4. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Author

Hegde, Sheila M., Claggett, Brian L., Wang, Xiaowen, Jering, Karola, Prasad, Narayana, Roshanali, Farideh, Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Abraham, Theodore P., Cardim, Nuno, Coats, Caroline J., Kramer, Christopher M., Maron, Martin S., Michels, Michelle, Olivotto, Iacopo, Saberi, Sara, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Meng, Lisa, Wohltman, Amy, Malik, Fady I., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

5. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

Author

Rao, Vishal N, Murray, Evan, Butler, Javed, Cooper, Lauren B, Cox, Zachary L, Fiuzat, Mona, Green, Jennifer B, Lindenfeld, JoAnn, McGuire, Darren K, Nassif, Michael E, O'Brien, Cara, Pagidipati, Neha, Sharma, Kavita, Vaduganathan, Muthiah, Vardeny, Orly, Fonarow, Gregg C, Mentz, Robert J, and Greene, Stephen J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Heart Disease, Clinical Research, Patient Safety, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Hypoglycemic Agents, Patient Discharge, Patient Readmission, Patient-Centered Care, Practice Guidelines as Topic, Randomized Controlled Trials as Topic, Risk, Sodium-Glucose Transporter 2, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, Ventricular Dysfunction, Left, &nbsp, guideline-directed medical therapy, heart failure, in-hospital prescribing, medical therapy, sodium-glucose cotransporter-2 inhibitors, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effects on blood pressure, and no excess risk of adverse kidney events. There is no evidence to suggest that deferring initiation to the outpatient setting accomplishes anything beneficial. Instead, there is compelling evidence that deferring in-hospital initiation exposes patients to excess risk of early postdischarge clinical worsening and death. Lessons from other heart failure with reduced ejection fraction therapies highlight that deferring initiation of guideline-recommended medications to the U.S. outpatient setting carries a >75% chance they will not be initiated within the next year. Recognizing that 1 in 4 patients hospitalized for worsening heart failure die or are readmitted within 30 days, clinicians should embrace the in-hospital period as an optimal time to initiate sodium-glucose cotransporter-2 inhibitor therapy and treat this population with the urgency it deserves.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results